Bell Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Bell Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-91	Closed	-$1.51K	–	1880
2025 Q1	$1.51K	Buy	91 +28	+44%	+$509	﹤0.01%	1409
2024 Q4	$1.16K	Hold	63	–	–	﹤0.01%	1540
2024 Q3	$969	Buy	+63	New	+$1.05K	﹤0.01%	1600
2024 Q1	–	Sell	-30	Closed	-$940	–	1910
2023 Q4	$940	Buy	+30	New	+$716	﹤0.01%	1614
2023 Q3	–	Sell	-19	Closed	-$456	–	1924
2023 Q2	$456	Buy	+19	New	+$422	﹤0.01%	1876
2022 Q3	–	Sell	-29	Closed	–	–	1699
2022 Q2	$0	Buy	+29	New	+$541	﹤0.01%	1713
2021 Q4	$4K	Buy	163 +134	+462%	+$2.69K	﹤0.01%	823
2021 Q3	$0	Buy	+29	New	+$559	﹤0.01%	1706

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Bell Investment Advisors's ACAD Position: Q2 2025 in Review

Bell Investment Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 91 shares — an estimated $1.51K sold.

Bell Investment Advisors first reported a position in ACAD in Q3 2021 and held it in 8 quarters. The position peaked at $4K in Q4 2021. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

Bell Investment Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Bell Investment Advisors sold 91 Acadia Pharmaceuticals shares in Q2 2025, an estimated $1.51K.
Bell Investment Advisors first reported a position in Acadia Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Bell Investment Advisors's Acadia Pharmaceuticals position peaked at $4K in Q4 2021.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Bell Investment Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.